US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

For RSV in particular, nearly two dozen states are currently reporting high levels, according to the U.S. Centers for Disease Control and Prevention ... and saline nasal spray Take over-the ...

Here is what to know about RSV, including its symptoms, treatment options and when to see a doctor. RSV is a common respiratory virus that causes mild, cold-like symptoms in healthy adults.